User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Nov 14 2016 01:57 IST RSS 2.0
 
1 to 20 of 2,754    
Bayer gets over compulsory licence 14.11.2016 ET: Pharma
“India is a large market and we will get through the challenges that are there. It is never easy but we also see huge potential in the Indian market which we cannot ignore.”
Also found in: [+]
IISC team designs 'salt' to combat bacterial infections 1.11.2016 TOI: Bangalore Times
While a combination of antibacterial and antimicrobial medications are used to treat infections, these can differ in their properties, some of which may not have the desired result. A physical mixture of the two drugs may not be very effective, said experts. A team from the Indian Institute of Science (IISc), Bengaluru, have addressed this problem by designing a solid in the form of a salt, which is a combination of two known drugs.
Also found in: [+]
Sitharaman discusses social security pact, IPR at Indo-US trade forum 20.10.2016 DNA: India
India, on Thursday, "strongly" urged the US to engage in negotiations for the Totalisation Agreement or Social Security pact as its absence is restricting the movement of domestic IT professionals in America. The issue of Totalisation Agreement was again taken up during a delegation-level meeting in New Delhi between the two nations. US Trade Representative Michael Froman is leading the delegation for the 10th India-US Trade Policy Forum (TPF) meeting. "We very clearly identified this as one of the non-tariff measures...which is restricting the movement of IT professionals. "We have strongly urged the US to engage in negotiations for signing of a Totalisation Agreement. It is being heard and I hope there will be a positive response from their side," Commerce and Industry Minister Nirmala Sitharaman told reporters after the delegation-level meeting. India wants early conclusion of the social security agreement with the US. The US has entered into Totalisation Agreement with several nations for the purpose ...
Also found in: [+]
India urges US to discuss pact to avoid double taxation 20.10.2016 TOI: India
India today "strongly" urged the US to engage in negotiations for the Totalisation Agreement or Social Security pact as its absence is restricting the movement of domestic IT professionals in America and also resulting in double taxation..
Also found in: [+]
Sun Pharma partners ICGEB to develop safer, cheaper dengue vaccine 20.10.2016 ET: Pharma
This is the Mumbai-based company’s second collaboration focussed on the mosquito-borne virus, the first being its pact to develop a botanical drug ‘Cipa’.
Also found in: [+]
India to be amongst top five global pharma innovation hubs by 2020: Assocham 29.8.2016 Sify Finance
[India], Aug 29 (ANI): To push India into top five pharmaceutical innovation hubs by 2020 and establish global presence by launching one out of every five to 10 drugs discovered in India at global
Also found in: [+]
Swamy attacks CEA Arvind Subramanian again 21.8.2016 TOI: Home
Swamy had in late June trained his guns on Arvind Subramanian and demanded his sacking for allegedly taking anti-India stance when he was an IMF economist at Washington prior to joining the Finance Ministry. Arun Jaitley had debunked Swamy's call saying "Government has full confidence in CEA."
Also found in: [+]
​ Pfizer plans to bring more global drugs to India 15.8.2016 ET: Pharma
Although the company sells most of its top 20 global products in India, it is looking to bring in a couple of drugs, the patents of which have expired, to the domestic market.
Also found in: [+]
Expanding markets, launching new products for growth: Wockhardt 14.8.2016 ET: Pharma
In the last 10 years, global research in antibiotics has declined and the number of patents filed globally has gone down by 60 per cent.
Also found in: [+]
Workhardt to expand markets, launch new products for growth 14.8.2016 DNA: Top News
Pharma major Wockhardt Ltd has said it is increasing investments in R&D, looking at expanding markets and launching new products to accelerate growth. "We have always believed that R&D is the key to the future. Naturally, we continue to increase our industry- leading investment in R&D as a percentage of total sales every year," Wockhardt Chairman and group CEO Habil Khorakiwala said at the company's annual general meeting (AGM). In the April - June quarter, Wockhardt's net profit plunged 83% to Rs 16 crore on the back of a dip in sales and increased expenditure, the company said.  "In FY16, our R&D spend of Rs 669 crore at 15% of total sales is almost 30% higher than our investment in R&D of Rs 515 crore at 11.5% of total sales in FY 15," he said. The company has various drugs at different stages of development, he said, adding: "We expect that in the next 3 to 5 years, we will have launched some of these drugs in Indian and global markets. Collectively, we are serving diverse patients with unmet needs ...
Also found in: [+]
MSF and Pfizer battle over patent application for life-saving pneumonia vaccine 29.7.2016 ET: Pharma
MSF filed declarations at the Delhi patent office to point out that Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13) was obvious and predictable.
Also found in: [+]
Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brands 27.7.2016 ET: Pharma
The acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.
Also found in: [+]
India rejects 955 pharma patent applications in last three years 25.7.2016 ET: Pharma
To a separate query, she said India is considered as a leading exporter and holds second position in export of generic drugs in terms of volumes.
Also found in: [+]
MSF urges India to continue pushing generic drugs 21.7.2016 DNA: Urban Tales
In a report presented on HIV drug pricing released at a conference in Durban on Thursday, the international medical humanitarian organisation Médecins Sans Frontières (MSF), also known as Doctors Without Borders, stressed on the need for India to encourage generic drugs. "India is under massive pressure to turn off its tap of affordable medicines, which are lifeline for millions of people not only in India, but across the developing world," said Leena Menghaney, South Asia Head of MSF's Access Campaign. "If India doesn't stand strong against pharmaceutical corporations and governments that are pushing for change in the country's patent law and policies, people around the world will face a crisis in access to medicines in the future," she said. While the prices of drugs of the first line and second line treatment have continued to fall, third line treatment remains expensive. The third line drugs are needed by people who have become resistant to other drugs. Cost of third line treatment for HIV can go up ...
Also found in: [+]
Granules to acquire 12.5 per cent stake in USpharma 14.7.2016 ET: Pharma
USpharma is a development-stage pharmaceutical company specialising in research, development and manufacture of high entry-barrier generic pharmaceuticals.
Also found in: [+]
India should reject efforts weakening access to generic drugs 7.7.2016 ET: Pharma
MSF urged Modi to defend India's lifeline to South Africa and developing countries through affordable versions of new medicines.
Also found in: [+]
Delhi High Court asks Roche to explain lawsuit over Avastin copy 24.5.2016 ET: Pharma
Roche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to bevacizumab.
Also found in: [+]
Pharma exports growth heading for a sharp decline, Crisil says 17.5.2016 TOI: India Business
ith the value of drugs going off-patent declining amid an increase in pricing pressures, exports growth in pharmaceutical formulations (in US dollar terms) would decline sharply to 10%-12% annually over the next five years, compared with a growth of about 19% achieved in the last decade, ratings agency Crisil has said.
Also found in: [+]
#dnaEdit: India must resist pressure to amend its patent laws 17.5.2016 DNA: Top News
The National Intellectual Property Rights (IPR) Policy promises to overhaul patents administration in India, but has raised concerns in the pharmaceutical industry and among those who seek a balance between IPR and free access to knowledge. Finance minister Arun Jaitley has asserted that India would retain its right to compulsory licensing in public interest to meet contingencies, and there would be no changes to Section 3(d) of the Indian Patents Act, which prevents ever-greening of drug patents. Though the policy claims that India’s patent laws are compliant with the Doha Declaration and the TRIPS (Trade Related Aspects of Intellectual Property Rights) Agreement, certain provisions in the policy document have alarmed the generic drugs industry. It promises to “carry out legislative changes” whenever existing laws become inadequate to address changes in the knowledge field.  With India constantly pressured by developed countries to amend its patent laws, it is feared that these changes can proceed only ...
Also found in: [+]
Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rights 16.5.2016 ET: Pharma
Legal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata Patent Office.
Also found in: [+]
1 to 20 of 2,754